- Infectious Diseases
- Cancer
- Other Therapeutic Areas
mRNA Vaccines Market size was valued at USD 10,753.4 million in 2023 and is poised to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030. mRNA vaccines represent a revolutionary approach to immunization, utilizing messenger RNA to instruct cells to produce proteins that trigger an immune response. This market encompasses various products and services essential for mRNA vaccine development and production, including lipid nanoparticles, nucleoside-modified mRNA, and related manufacturing technologies. The mRNA vaccines market serves a diverse range of indications, from infectious diseases to cancer immunotherapy and rare genetic disorders.
Its indications span across preventive and therapeutic use, addressing the needs of various patient populations. The growth of the mRNA vaccines market is driven by factors such as the success of COVID-19 mRNA vaccines, increased investment in biotechnology, and the potential for rapid vaccine development against emerging threats. For instance, according to WHO data, over 5.47 billion doses of COVID-19 vaccines, including mRNA vaccines, had been administered globally by early 2023. Moreover, the pandemic has accelerated research into mRNA technology for other diseases, further boosting market expansion. However, challenges such as cold chain requirements, production scalability, and regulatory hurdles may impact market growth to some extent.
mRNA Vaccines Market key Developments:
- On March 26, 2024, Moderna, Inc. announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
- On July 16, 2024, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, recently confirmed that the company’s Life Science business entered into a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform.
mRNA Vaccines Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
9.0%
Largest Market
North America
Fastest Growing Market
Asia Pacific
mRNA Vaccines Market Dynamics
The increasing global focus on pandemic preparedness, coupled with the growing burden of infectious diseases and cancer, has intensified the demand for innovative vaccine technologies. mRNA vaccines offer several advantages over traditional vaccines, including rapid development and manufacturing, as well as the potential for multi-disease platforms. These factors contribute to the expanding adoption of mRNA vaccine technology worldwide. Furthermore, technological advancements in mRNA delivery systems and production processes have enhanced vaccine efficacy and stability. The development of improved lipid nanoparticle formulations, optimized mRNA sequences, and novel manufacturing techniques have addressed many historical challenges associated with mRNA vaccines. Additionally, the shift towards personalized medicine and the emphasis on targeted therapies have favored the growth of mRNA-based approaches, particularly in cancer immunotherapy. This trend has been further accelerated by the success of COVID-19 mRNA vaccines, which demonstrated the platform's potential on a global scale. As healthcare systems worldwide strive to improve vaccine accessibility and efficacy, mRNA technology is increasingly recognized as a promising solution for addressing both established and emerging health threats.
North-America Got Significant Share
mRNA Vaccines Market Regional Analysis
Based on regions the mRNA vaccines market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. In 2022, North America accounted for the largest revenue share in the mRNA vaccines market. The region's dominance is attributed to robust research infrastructure, substantial investment in biotechnology, and early adoption of mRNA vaccine technology. The United States, in particular, has seen significant advancements in mRNA vaccine development and production capabilities, supported by initiatives like Operation Warp Speed. The Asia-Pacific region is expected to witness the most rapid growth in the mRNA vaccines market. This expansion is fueled by increasing government support for vaccine development, growing healthcare expenditure, and rising awareness of the potential of mRNA technology. Countries like China and India are investing heavily in mRNA vaccine research and manufacturing facilities, driving the demand for related products and services. For instance, China approved its first domestically developed mRNA COVID-19 vaccine for emergency use in 2023.
Latin America
Europe
Asia Pacific
Middle East
North America
mRNA Vaccines Market Segmentation
By Indication
By Type
- Prophylactic Vaccines
- Therapeutic Vaccines
By End User
- Hospitals and Clinics
- Research Institutions
- Others
Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The global mRNA vaccines market size was valued at USD 10,753.4 million in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2030.
The global mRNA vaccines market is segmented based on indication, type, end-user, and geography.
The leading players in the global mRNA vaccines market include Moderna, Inc., Pfizer Inc. (in partnership with BioNTech SE), CureVac N.V., Sanofi, GlaxoSmithKline plc, Arcturus Therapeutics Holdings Inc., BioNTech SE, and others.
The expansion of the mRNA vaccines market is driven by the success of COVID-19 mRNA vaccines, increasing investment in biotechnology, the potential for rapid vaccine development, and growing applications in cancer immunotherapy.
Cold chain storage requirements, production scalability challenges, and regulatory hurdles for new mRNA vaccines hamper the global mRNA vaccines market. Public hesitancy and competition from traditional vaccine technologies may also hinder market growth.
Key Features of the Report
- The mRNA vaccines market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global mRNA Vaccines Market Introduction |
| 2.1.Global mRNA Vaccines Market - Taxonomy |
| 2.2.Global mRNA Vaccines Market - Definitions |
| 2.2.1.Indication |
| 2.2.2.Type |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global mRNA Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global mRNA Vaccines Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global mRNA Vaccines Market By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Infectious Diseases |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Cancer |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Other Therapeutic Areas |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global mRNA Vaccines Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Prophylactic Vaccines |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Therapeutic Vaccines |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global mRNA Vaccines Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals and Clinics |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Research Institutions |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global mRNA Vaccines Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America mRNA Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Infectious Diseases |
| 9.1.2.Cancer |
| 9.1.3.Other Therapeutic Areas |
| 9.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Prophylactic Vaccines |
| 9.2.2.Therapeutic Vaccines |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals and Clinics |
| 9.3.2.Research Institutions |
| 9.3.3.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe mRNA Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Infectious Diseases |
| 10.1.2.Cancer |
| 10.1.3.Other Therapeutic Areas |
| 10.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Prophylactic Vaccines |
| 10.2.2.Therapeutic Vaccines |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals and Clinics |
| 10.3.2.Research Institutions |
| 10.3.3.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) mRNA Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Infectious Diseases |
| 11.1.2.Cancer |
| 11.1.3.Other Therapeutic Areas |
| 11.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Prophylactic Vaccines |
| 11.2.2.Therapeutic Vaccines |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals and Clinics |
| 11.3.2.Research Institutions |
| 11.3.3.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) mRNA Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Infectious Diseases |
| 12.1.2.Cancer |
| 12.1.3.Other Therapeutic Areas |
| 12.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Prophylactic Vaccines |
| 12.2.2.Therapeutic Vaccines |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals and Clinics |
| 12.3.2.Research Institutions |
| 12.3.3.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America mRNA Vaccines Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Infectious Diseases |
| 13.1.2.Cancer |
| 13.1.3.Other Therapeutic Areas |
| 13.2. Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Prophylactic Vaccines |
| 13.2.2.Therapeutic Vaccines |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals and Clinics |
| 13.3.2.Research Institutions |
| 13.3.3.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Moderna, Inc. |
| 14.2.2.Pfizer Inc. (in partnership with BioNTech SE) |
| 14.2.3.CureVac N.V. |
| 14.2.4.Sanofi |
| 14.2.5.GlaxoSmithKline plc |
| 14.2.6.Arcturus Therapeutics Holdings Inc. |
| 14.2.7.BioNTech SE |
| 14.2.8.Translate Bio (acquired by Sanofi) |
| 14.2.9.eTheRNA immunotherapies NV |
| 14.2.10.Ethris GmbH |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Moderna, Inc.
- Pfizer Inc. (in partnership with BioNTech SE)
- CureVac N.V.
- Sanofi
- GlaxoSmithKline plc
- Arcturus Therapeutics Holdings Inc.
- BioNTech SE
- Translate Bio (acquired by Sanofi)
- eTheRNA immunotherapies NV
- Ethris GmbH